Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled Phase 2b Study to Establish the Effective Dose Range and to Evaluate the Safety of Chrysalin in Adult Subjects With a Fractured Distal Radius

NCT00131482 is registered in ClinicalTrials.gov with Capstone Therapeutics as lead sponsor.

NCT NCT00131482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00131482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled Phase 2b Study to Establish the Effective Dose Range and to Evaluate the Safety of Chrysalin in Adult Subjects With a Fractured Distal Radius
Lead sponsor
Capstone Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2004
Completion date
March 31, 2007
Enrollment
274 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

radius fracture